Celerion has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project, a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical services to support the development of pharmacodynamic measures with the goal of creating industry standards.
The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH aims to discover, develop, and qualify biomarkers to support drug development, preventive medicine, and medical diagnostics.
“Celerion has continued to invest in and expand our capabilities in metabolic disease to support early Proof-of-Concept studies in the development of diabetes, obesity, metabolic and cardio-metabolic interventions. We are therefore delighted to have been selected to support programs by the FNIH in the area of metabolic disorders,” said Philip Bach, vice president of Global Clinical Research at Celerion. “The award of this program, and knowing that our contribution will help set industry standards, is recognition of our expertise in this area and the quality of data delivered to clients.”